RT Journal Article
SR Electronic
T1 Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.10.21253288
DO 10.1101/2021.03.10.21253288
A1 Eberhardt, Kirsten Alexandra
A1 Dewald, Felix
A1 Heger, Eva
A1 Gieselmann, Lutz
A1 Vanshylla, Kanika
A1 Wirtz, Maike
A1 Kleipass, Franziska
A1 Johannis, Wibke
A1 Schommers, Philipp
A1 Gruell, Henning
A1 Brensing, Karl August
A1 Müller, Roman-Ulrich
A1 Augustin, Max
A1 Lehmann, Clara
A1 Koch, Manuel
A1 Klein, Florian
A1 Di Cristanziano, Veronica
YR 2021
UL http://medrxiv.org/content/early/2021/03/18/2021.03.10.21253288.abstract
AB Background The investigation of antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared one new and four widely used commercial serological assays for the detection of antibodies targeting S (spike) and NC (nucleocapsid) protein.Methods Serum samples from a group of apparently non-responders, from an unbiased group of convalescent patients and from a negative control group were sim-ultaneously analyzed by the LIAISON® SARS-CoV-2 S1/S2 IgG test, Euroimmun anti-SARS-CoV-2 S1 IgG ELISA and IDK® anti-SARS-CoV-2 S1 IgG assays. IgG binding NC were detected by the Abbott SARS-CoV-2 IgG assay and by the panimmunoglobulin immunoassay Elecsys® Anti-SARS-CoV-2. Additionally, samples were also tested by live virus and pseudovirus neutralization tests.Results Overall, about 50% of convalescent patients with undetectable IgG antibodies using the commercial kit by Euroimmun were identified as IgG positive by Immundiagnostik and Roche. While both assays achieved similarly high sensitivities, Immundiagnostik correlated better with serum neutralizing activity than Roche.Conclusions Although the proportion of IgG seropositive individuals appears to be higher using more sensitive immunoassays, the protective ability and the potential to serve as indirect markers of other beneficial immune responses warrants for further research.Competing Interest StatementThe University of Cologne (Medical Faculty) receives royalties from Immundiagnostik (IDK) for the co-development of the IDK anti-SARS-CoV-2 IgG ELISA and IDK anti-SARS-CoV-2 IgM ELISA kits. However, until now no royalty has been paid. We expect within the next months some royalties being paid. IDK had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.Funding StatementThis work was funded by grants from the German Center for Infection Research (DZIF to F.K.), the German Research Foundation (DFG; CRC 1279, F.K.; CRC 1310, F.K.; FOR2722, M.K.), the European Research Council (ERC-StG639961, F.K.), and COVIM: NaFoUniMedCovid19 (FKZ: 01KX2021).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were collected and analyzed under protocols approved by the Institutional Review Board of the University of Cologne, Germany (16-054 and 20-1187)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDataset analyzed during the current study is available in supplementary materials.